AMD--the retinal disease with an unprecised etiopathogenesis: in search of effective therapeutics.
AMD (age-related macular degeneration) is a progressive vision-threatening ocular disease, affecting central region of the retina--the macula--and manifesting in the elderly. AMD is a degenerative disease, and the degeneration affects primarily the retinal pigment epithelial (RPE) cells and secondarily the photoreceptors, leading consequently to disturbances or partial loss of central vision and legal blindness. Clinically, the disease is classified as: atrophic--dry AMD (in majority of cases), and neovascular--wet AMD (with choroidal neovascularization--CNV: 10-15% of all AMD cases). Pathogenesis of AMD is complex, multifactorial and only poorly recognized. Main risk factors include: advanced age, genetic predispositions, environmental determinants, history of exposure to intensive light and smoking. At least four molecular processes contribute to the development of AMD pathology: lipofuscinogenesis, drusogenesis, inflammation and choroidal neovascularization (in wet AMD). Since vascular endothelial growth factor (VEGF) is a predominant proangiogenic factor in CNV. the wet AMD can be treated with intravitreous application of "anti-VEGF" agents (Avastin, Lucentis, Eylea). Till now, there is no approved therapy for dry AMD, although several agents/treatments are currently in clinical trials. This paper briefly describes major molecular and cellular events leading to AMD, and presents currently used and new experimental therapeutic strategies against AMD.
Jerzy Z
JZ
Nowak
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D002986:Clinical Trials as Topic; D019587:Dietary Supplements; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D018384:Oxidative Stress / Q000187:drug effects; D010778:Photochemotherapy / Q000379:methods; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D018696:Neuroprotective Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A